Lower serum albumin levels at diagnosis are independently associated with higher 2-year all-cause mortality in patients with wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to a recent study published in Acta Cardiologica.
In a cohort of 129 patients, those with serum albumin levels of 3.88 g/dL or less (36% of the group) experienced a 51% mortality rate at 2 years, compared with 12% for patients with higher levels (P <.001), with the association holding in multivariable models adjusted for age, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and heart failure at diagnosis.
This retrospective analysis focused on the prognostic role of nutritional status in wild-type ATTR-CM. Current staging systems rely on cardiac biomarkers such as NT-proBNP and troponin but do not incorporate nutritional status, even though patients with wild-type ATTR-CM frequently develop cardiac cachexia